AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26555870 — intervention group
Group type: EXPERIMENTAL
Intervention: Two periods of 15 minutes of active air-forced warming before and after EDA (n=34)
Number of subjects: 99
Study 26555870 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation (control group, n=32)
Number of subjects: 99
Study 24675683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting implementation intentions (e.g., If I open the fridge I will think of dieting!)
Number of subjects: 0
Study 24675683 — intervention group
Group type: EXPERIMENTAL
Intervention: Food go/no-go task (behavioral stop signals presented upon presentation of palatable foods)
Number of subjects: 0
Study 24675683 — intervention group
Group type: COMPARATOR
Intervention: Control implementation intentions
Number of subjects: 0
Study 24675683 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli for go/no-go task
Number of subjects: 0
Study 22269428 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin plus cisplatin-pemetrexed (125 or 250 mg twice daily)
Number of subjects: 22
Study 22269428 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin-pemetrexed
Number of subjects: 22
Study 20844184 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 34
Study 17623381 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIP programme (n = 44)
Number of subjects: 81
Study 17623381 — intervention group
Group type: COMPARATOR
Intervention: Traditional ward occupational therapy (WOT) programme (n = 37)
Number of subjects: 81
Study 16041193 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl and ezetimibe combination therapy
Number of subjects: 12
Study 11993618 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol loading (1.2 g of glycerol per kg of body mass and 25 ml of a 0.75 g x kg(‐1) BM carbohydrate solution consumed over 60 minutes, 2 hours prior to ODT)
Number of subjects: 10
Study 11993618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11993618 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol loading
Number of subjects: 10
Study 10568224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus calcium (10 mg alendronate + 500 mg calcium/day)
Number of subjects: 152
Study 10568224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus calcitriol (0.25 microgram synthetic 1,25‐dihydroxyvitamin D3 + 10 mg alendronate)
Number of subjects: 152
Study 10568224 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 152
Study 7725591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tymoptin (T)
Number of subjects: 148
Study 7725591 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nucleinate (SN)
Number of subjects: 148
Study 7725591 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigiosan (PR)
Number of subjects: 148
Study 7725591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SN + PR
Number of subjects: 148
Study 7725591 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 148
Study 2183488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg intramuscular (im)
Number of subjects: 57
Study 2183488 — intervention group
Group type: COMPARATOR
Intervention: Baralgin 5 mL intravenous (iv)
Number of subjects: 57
Study 7033848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride (active group)
Number of subjects: 195
Study 7033848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 195
Study 31140343 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP intervention in the intervention group (34 GP practices)
Number of subjects: 700
Study 31140343 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 GP practices)
Number of subjects: 700
Study 31140343 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP intervention in the intervention group
Number of subjects: 700
Study 29733770 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 320
Study 26671216 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot only (60 minutes of robotic therapy)
Number of subjects: 22
Study 26671216 — intervention group
Group type: COMPARATOR
Intervention: Robot + TTT (45 minutes on the robot plus 15 minutes of translation‐to‐task practice)
Number of subjects: 22
Study 26671216 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot only
Number of subjects: 22
Study 26671216 — intervention group
Group type: COMPARATOR
Intervention: Robot + TTT
Number of subjects: 22
Study 25214041 — intervention group
Group type: EXPERIMENTAL
Intervention: biCEBPA mutations
Number of subjects: 88
Study 25214041 — intervention group
Group type: COMPARATOR
Intervention: moCEBPA mutations
Number of subjects: 88
Study 25214041 — intervention group
Group type: EXPERIMENTAL
Intervention: biCEBPA mutations in patients ≤ 60 years
Number of subjects: 88
Study 22898992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg, single dose)
Number of subjects: 0
Study 22898992 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (1 ‐ 2 µg/kg/min)
Number of subjects: 0
Study 20100120 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% NaF mouthwash
Number of subjects: 9
Study 20100120 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% NaF toothpaste
Number of subjects: 9
Study 20100120 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaF-impregnated Miswaks
Number of subjects: 9
Study 20100120 — intervention group
Group type: COMPARATOR
Intervention: 0.32% NaF toothpaste
Number of subjects: 9
Study 20100120 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF mouthwash
Number of subjects: 9
Study 20100120 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF-impregnated Miswaks
Number of subjects: 9
Study 17299109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (laparoscopic Roux-en-Y gastric bypass, n = 21; laparoscopic adjustable gastric banding, n = 5)
Number of subjects: 26
Study 15611850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapeutic treatment program (n=10)
Number of subjects: 21
Study 15611850 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=11)
Number of subjects: 21
Study 12218617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) with 60 microg and 100 mg hydrocortisone for 7 days
Number of subjects: 57
Study 12218617 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 100 mg hydrocortisone
Number of subjects: 57
Study 10624762 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge (concentration up to 128 mg x mL(‐1))
Number of subjects: 8
Study 7496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (150 mg/h)
Number of subjects: 0
Study 7496872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2044501 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) 50 mg/kg per day (maximum 3,000 mg)
Number of subjects: 30
Study 2044501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7019201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily doses of amoxapine
Number of subjects: 35
Study 7019201 — intervention group
Group type: COMPARATOR
Intervention: Divided daily doses of amoxapine
Number of subjects: 35
Study 31229956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SpO2 target (85%-89%)
Number of subjects: 984
Study 31229956 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SpO2 target (91%-95%)
Number of subjects: 984
Study 31229956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation duration
Number of subjects: 984
Study 31229956 — intervention group
Group type: COMPARATOR
Intervention: Other risk factors
Number of subjects: 984
Study 29485926 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (lactated Ringer's solution or Plasma‐Lyte A)
Number of subjects: 13347
Study 29485926 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 13347
Study 27108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive pedaling exercise
Number of subjects: 10
Study 27108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pedaling exercise
Number of subjects: 10
Study 27108543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedaling (both passive and active)
Number of subjects: 10
Study 25197921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized fibrin sealant (FS)
Number of subjects: 41
Study 25197921 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl acetal sponge packing
Number of subjects: 41
Study 23033003 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy (specifics not provided)
Number of subjects: 0
Study 21137794 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-SQ cream applied twice daily on one half of the face
Number of subjects: 23
Study 21137794 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-SQ cream
Number of subjects: 23
Study 21137794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (squalane blended cream without fullerene-C60)
Number of subjects: 23
Study 18201449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole, 20 mg, orally twice daily for 90 days
Number of subjects: 47
Study 18201449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15797496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose pulsed shortwave (10 W)
Number of subjects: 27
Study 15797496 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose pulsed shortwave (20 W)
Number of subjects: 27
Study 15797496 — intervention group
Group type: COMPARATOR
Intervention: Placebo high frequency pulsed shortwave
Number of subjects: 27
Study 12372721 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant chemotherapy
Number of subjects: 13
Study 12372721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic-artery-based chemotherapy or embolisation
Number of subjects: 13
Study 12372721 — intervention group
Group type: EXPERIMENTAL
Intervention: Other therapeutic modalities (immunological, radiation, differentiation agents)
Number of subjects: 13
Study 12372721 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic chemotherapy
Number of subjects: 13
Study 9657512 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 56697
Number of subjects: 260
Study 9657512 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 260
Study 7977112 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 204
Study 7977112 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 204
Study 2686455 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptives (1) ethinyl estradiol 30, 40, 30 micrograms/day and levonorgestrel 50, 75, 125 micrograms/day; (2) ethinyl estradiol 35 micrograms/day and phased norethindrone 500, 750, 1000 micrograms/day; (3) ethinyl estradiol 35 micrograms/day and norethindrone 500, 1000, 500 micrograms/day
Number of subjects: 150
Study 2686455 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonhormonal contraception)
Number of subjects: 150
Study 31734734 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product (Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2) 109 CFU once daily for 3 months
Number of subjects: 131
Study 31734734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 31734734 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product
Number of subjects: 131
Study 31734734 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic product (projected data)
Number of subjects: 131
Study 29332761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention in Group 1 (symptomatic knee OA)
Number of subjects: 42
Study 29332761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention in Group 2 (asymptomatic knee OA)
Number of subjects: 42
Study 29332761 — intervention group
Group type: COMPARATOR
Intervention: No intervention in Group 3 (control group)
Number of subjects: 42
Study 26643066 — intervention group
Group type: EXPERIMENTAL
Intervention: 38Checkpain checklist for pain control
Number of subjects: 92
Study 26643066 — intervention group
Group type: COMPARATOR
Intervention: Standard practice without the 38Checkpain checklist
Number of subjects: 92
Study 24356798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal method (MMM) using indocyanine green (ICG), radioisotope (RI), and blue dye (BD)
Number of subjects: 86
Study 24356798 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope (RI) alone
Number of subjects: 86
Study 24356798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal method (MMM)
Number of subjects: 86
Study 22319592 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg PO/day, increased every three days by 1 mg up to 4 mg)
Number of subjects: 13
Study 22319592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo lactose)
Number of subjects: 13
Study 20521064 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA supplementation
Number of subjects: 29
Study 20521064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 29
Study 20521064 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA group
Number of subjects: 29
Study 18394742 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional retraining programme with daily isokinetic reinforcement of the trunk muscles
Number of subjects: 60
Study 18394742 — intervention group
Group type: COMPARATOR
Intervention: Functional retraining programme without daily isokinetic reinforcement of the trunk muscles (Control Group)
Number of subjects: 60
Study 16107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 0
Study 16107596 — intervention group
Group type: COMPARATOR
Intervention: No taurine supplementation (Control)
Number of subjects: 0
Study 16107596 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation in infants with necrotizing enterocolitis (NEC)
Number of subjects: 0
Study 16107596 — intervention group
Group type: COMPARATOR
Intervention: No taurine supplementation in infants with necrotizing enterocolitis (NEC) (Control)
Number of subjects: 0
Study 14534891 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg)
Number of subjects: 1648
Study 14534891 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg)
Number of subjects: 1648
Study 11012611 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of pulmonary TB for 6 months
Number of subjects: 49
Study 11012611 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 49
Study 11012611 — intervention group
Group type: COMPARATOR
Intervention: Asthma patients (no treatment)
Number of subjects: 49
Study 8858276 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 17
Study 8858276 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 17
Study 7678931 — intervention group
Group type: EXPERIMENTAL
Intervention: finasteride 1 mg/day and finasteride 5 mg/day (combined results)
Number of subjects: 20
Study 7678931 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29683919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 250
Study 29683919 — intervention group
Group type: COMPARATOR
Intervention: Current exercise guidelines (30 min·d moderate-intensity exercise)
Number of subjects: 250
Study 28144978 — intervention group
Group type: EXPERIMENTAL
Intervention: Team training (TG)
Number of subjects: 72
Study 28144978 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 72
Study 28144978 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 72
Study 27193736 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance on protective feeding practices
Number of subjects: 698
Study 27193736 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 698
Study 23574097 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-rich teaching
Number of subjects: 54
Study 23574097 — intervention group
Group type: COMPARATOR
Intervention: Low memory instruction
Number of subjects: 54
Study 21467697 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 705 mg orally before and 12, 24, 36 hours after primary angioplasty)
Number of subjects: 76
Study 21467697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 21467697 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 76
Study 21467697 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) and Placebo
Number of subjects: 76
Study 19525846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg daily)
Number of subjects: 135
Study 19525846 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg daily)
Number of subjects: 135
Study 16461864 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (n = 198) with abstinence incentives during a 12-week trial.
Number of subjects: 388
Study 16461864 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 190) without abstinence incentives during a 12-week trial.
Number of subjects: 388
Study 15505610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, carmustine, and thiotepa (CBT) followed by autologous hematopoietic stem cell transplantation (AHST)
Number of subjects: 177
Study 15505610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CBT followed by AHST
Number of subjects: 177
Study 11775651 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG)
Number of subjects: 30
Study 11775651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8712429 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (0.5%, 0.8%, or 1.1% end‐tidal) in N2O (66% end‐tidal)
Number of subjects: 12
Study 8712429 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (1.1% end‐tidal)
Number of subjects: 12
Study 8712429 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of consciousness
Number of subjects: 12
Study 1888641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 2.0 mg
Number of subjects: 0
Study 1888641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 1.0 mg and 2.0 mg
Number of subjects: 0
Study 1888641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6669636 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg zopiclone
Number of subjects: 10
Study 6669636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zopiclone
Number of subjects: 10
Study 6669636 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 10
Study 6669636 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zopiclone
Number of subjects: 10
Study 6669636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30661639 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized 10-item short form (EF10)
Number of subjects: 1028
Study 30661639 — intervention group
Group type: COMPARATOR
Intervention: Common EORTC Quality of Life Questionnaire Core 30 four-item scale (EF4)
Number of subjects: 1028
Study 28285042 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with a highly capable adult in half of the dialogs
Number of subjects: 0
Study 28285042 — intervention group
Group type: COMPARATOR
Intervention: Peer-only dialogs
Number of subjects: 0
Study 25560444 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict rest for 5 days
Number of subjects: 99
Study 25560444 — intervention group
Group type: COMPARATOR
Intervention: Usual care (1‐2 days rest, followed by stepwise return to activity)
Number of subjects: 99
Study 23726161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated alum-adjuvant EV71 vaccine
Number of subjects: 10245
Study 23726161 — intervention group
Group type: COMPARATOR
Intervention: Alum-adjuvant placebo
Number of subjects: 10245
Study 21897013 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation 1 mg/d for 4 or 12 weeks
Number of subjects: 20
Study 21897013 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation 3 mg/d for 4 or 12 weeks
Number of subjects: 20
Study 20046641 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 30
Study 17711716 — intervention group
Group type: COMPARATOR
Intervention: Regional longitudinal ventricular systolic velocities (R1is, R2is, R2ez, R3is, S1is, S1ez, S2ez, L1is, L1ez, L2ez) in group A (patients with cardiac events)
Number of subjects: 42
Study 17711716 — intervention group
Group type: COMPARATOR
Intervention: VO(2max)
Number of subjects: 42
Study 15507582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 112
Study 15507582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 112
Study 15507582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CBT and sertraline
Number of subjects: 112
Study 15507582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 12102584 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal treatment in a minimal therapist contact (MTC) format
Number of subjects: 20
Study 12102584 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 20
Study 9158630 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors (statins)
Number of subjects: 20438
Study 9158630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20438
Study 8129214 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 (800 mg daily)
Number of subjects: 16
Study 8129214 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur (800 mg daily)
Number of subjects: 16
Study 2914061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation for 24 hours
Number of subjects: 45
Study 2914061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation for 34 hours
Number of subjects: 45
Study 1093461 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-dose heparin
Number of subjects: 150